专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明申请

US20130288266A1 DETECTION OF A POSTTRANSLATIONALLY MODIFIED POLYPEPTIDE BY A BI-VALENT BINDING AGENT 审中-公开
标题翻译：通过一个双向绑定剂检测后置改性的多肽
公开(公告)号：US20130288266A1
公开(公告)日：2013-10-31
申请号：US13923618
申请日：2013-06-21
申请人： Michael Gerg , Dieter Heindl , Christian Klein , Alfred Mertens , Volker Schmid , Michael Schraeml , Monika Soukupova , Michael Tacke
发明人： Michael Gerg , Dieter Heindl , Christian Klein , Alfred Mertens , Volker Schmid , Michael Schraeml , Monika Soukupova , Michael Tacke
IPC分类号： C07K16/46
CPC分类号： C07K16/468 , G01N33/531
摘要： A bi-valent binding agent having a first monovalent binder that binds to a polypeptide epitope of a target polypeptide, a second monovalent binder that binds to a posttranslational polypeptide modification on the target polypeptide and a linker. Further disclosed are methods for the detection of a posttranslationally modified target polypeptide, for making the disclosed bi-valent binding agent, and for use of the disclosed bi-valent binding agent in histological staining procedures.
摘要翻译：具有结合靶多肽的多肽表位的第一单价结合剂的双价结合剂，与靶多肽上的翻译后多肽修饰结合的第二单价粘合剂和接头。进一步公开的是用于检测翻译后修饰的靶多肽，用于制备所公开的双价结合剂的方法，以及用于所公开的双价结合剂在组织学染色程序中的方法。

22. 发明申请

US20120196303A1 CYBP AS A MARKER FOR LUNG CANCER 有权
标题翻译： CYBP作为肺癌标志物
公开(公告)号：US20120196303A1
公开(公告)日：2012-08-02
申请号：US13270482
申请日：2011-10-11
申请人： Herbert Andres , Johann Karl , Julia Riedlinger , Markus Roessler , Michael Tacke , Michael Thierolf
发明人： Herbert Andres , Johann Karl , Julia Riedlinger , Markus Roessler , Michael Tacke , Michael Thierolf
IPC分类号： G01N33/53
CPC分类号： G01N33/57423 , G01N2333/4727
摘要： The present invention relates to the assessment of lung cancer. It discloses the use of protein CYBP in the assessment of lung cancer. It also relates to a method for assessing lung cancer in vitro using a liquid sample, derived from an individual by measuring CYBP in said sample. Measurement of CYBP can, e.g., be used in the early detection or in the follow-up of patients with lung cancer.
摘要翻译：本发明涉及肺癌的评估。它公开了蛋白CYBP在肺癌评估中的应用。它还涉及一种通过在所述样品中测量CYBP在体外使用来自个体的液体样品来评估肺癌的方法。 CYBP的测量可以例如用于肺癌患者的早期检测或随访。

23. 发明申请

US20110275100A1 SERPIN B 13 AS A MARKER FOR SQUAMOUS CELL CARCINOMA OF THE LUNG 失效
标题翻译： SERPIN B 13作为肺鳞状细胞癌的标记物
公开(公告)号：US20110275100A1
公开(公告)日：2011-11-10
申请号：US13186750
申请日：2011-07-20
申请人： Markus Roessler , Liliana Mantovani-Endl , Michael Tacke
发明人： Markus Roessler , Liliana Mantovani-Endl , Michael Tacke
IPC分类号： G01N33/566 , G01N33/574
CPC分类号： G01N33/57423 , G01N2333/8121
摘要： Disclosed is a method aiding in the assessment of squamous cell carcinoma (SCC). It involves the use of the protein serpin B13 as a marker of SCC. Furthermore, the disclosure relates to a method for assessing lung cancer in a tissue sample derived from a patient having non-small cell lung carcinoma (NSCLC) and for differentiating SCC from adenocarcinoma or large cell carcinoma of the lung.
摘要翻译：公开了一种辅助评估鳞状细胞癌（SCC）的方法。它涉及使用蛋白丝氨酸蛋白酶B13作为SCC的标记。此外，本公开涉及一种用于评估源自具有非小细胞肺癌（NSCLC）的患者并用于将SCC与腺癌或肺的大细胞癌分化的组织样品中的肺癌的方法。

24. 发明授权

US5783158A Process for treating sulfide ores containing gold and/or silver and as accompanying metal at least iron 失效
标题翻译：用于处理含有金和/或银的硫化矿石和至少铁的伴随金属的方法
公开(公告)号：US5783158A
公开(公告)日：1998-07-21
申请号：US805462
申请日：1997-02-25
申请人： Michael Tacke , Walter Pierson , Eberhard Stolarski
发明人： Michael Tacke , Walter Pierson , Eberhard Stolarski
IPC分类号： C22B1/02 , C22B1/06 , C22B1/10 , C22B11/00 , C22B1/00 , C22B11/08
CPC分类号： C22B1/10 , C22B1/06 , C22B11/04
摘要： The ore which contains gold and/or silver and as accompanying metal at least iron is calcined at temperatures in the range from 500.degree. to 900.degree. C. with the addition of oxygen-containing gas. There is obtained a metal-oxide-containing solids mixture and a SO.sub.2 -containing exhaust gas. The solids mixture from the calcination is cooled, the temperature being reduced by at least 50.degree. C. The cooled solids mixture is added to a fluidized-bed reactor, and SO.sub.2 -containing exhaust gas is introduced into the fluidized-bed reactor. In the reactor, metal sulfate is produced in the solids mixture, so that at least 10% of the sulfur content are bound in the exhaust gas. Solids mixture containing metal sulfate is withdrawn from the fluidized-bed reactor, is stirred up with an aqueous acid solution, thereby dissolving metal sulfate. The remaining solids are supplied to a recovery of gold and/or silver.
摘要翻译：含有金和/或银以及至少铁的伴随金属的矿石在500-900℃的温度下煅烧，同时加入含氧气体。得到含有金属氧化物的固体混合物和含SO 2的废气。将来自煅烧的固体混合物冷却，将温度降低至少50℃。将冷却的固体混合物加入流化床反应器中，将含SO 2的废气引入流化床反应器中。在反应器中，在固体混合物中产生金属硫酸盐，使得至少10％的硫含量结合在废气中。从流化床反应器中取出含有金属硫酸盐的固体混合物，用酸水溶液搅拌，从而溶解金属硫酸盐。剩余的固体被提供到金和/或银的回收。

25. 发明申请

US20110212464A1 PACAP AS A MARKER FOR CANCER 审中-公开
标题翻译： PACAP作为癌症标记
公开(公告)号：US20110212464A1
公开(公告)日：2011-09-01
申请号：US13099562
申请日：2011-05-03
申请人： Marie-Luise Hagmann , Johann Karl , Julia Kloeckner , Markus Roessler , Michael Tacke
发明人： Marie-Luise Hagmann , Johann Karl , Julia Kloeckner , Markus Roessler , Michael Tacke
IPC分类号： G01N33/68 , C12Q1/527 , C12Q1/02
CPC分类号： G01N33/57407 , G01N33/57423
摘要： The present invention relates to a method aiding in the assessment of cancer. It discloses the use of the proapoptotic caspase adaptor protein (=PACAP) as a universal marker of different types of cancer. PACAP aids in the assessment of pulmonary or lung cancer (LC), particularly of non-small cell lung carcinoma (NSCLC), but also of other specific types of cancer. Such specific types of cancer are e.g. colon, bladder, cervix, ovary, endometrial, head and neck, breast, melanoma, pancreas, kidney, prostate, esophagus, stomach or bile duct cancer. Furthermore, the present invention especially relates to a method for assessing cancer from a liquid sample, derived from an individual by measuring PACAP in said sample. Measurement of PACAP can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.
摘要翻译：本发明涉及一种协助癌症评估的方法。它公开了促凋亡半胱天冬酶衔接蛋白（= PACAP）作为不同类型癌症的通用标记物的使用。 PACAP有助于评估肺或肺癌（LC），特别是非小细胞肺癌（NSCLC），还有其他特定类型的癌症。这些特定类型的癌症是例如。结肠，膀胱，子宫颈，卵巢，子宫内膜，头颈部，乳腺，黑素瘤，胰腺，肾，前列腺，食道，胃或胆管癌。此外，本发明特别涉及通过测量所述样品中的PACAP从个体得到的从液体样品中评估癌症的方法。 PACAP的测量可以例如用于癌症的早期检测或用于进行手术的患者的监视。

26. 发明申请

US20100240081A1 SEPRASE AS A MARKER FOR CANCER 有权
标题翻译： SEPRASE作为癌症的标记
公开(公告)号：US20100240081A1
公开(公告)日：2010-09-23
申请号：US12791946
申请日：2010-06-02
申请人： Wolfgang Rollinger , Johann Karl , Jarema Peter Kochan , Markus Roessler , Michael Tacke
发明人： Wolfgang Rollinger , Johann Karl , Jarema Peter Kochan , Markus Roessler , Michael Tacke
IPC分类号： C12Q1/48 , C12Q1/37
CPC分类号： G01N33/57423 , G01N33/57407 , G01N33/57419 , G01N33/57473 , G01N2333/96411
摘要： The present invention relates to a method aiding in the assessment of cancer. It discloses the use of the human fibroblast activation protein (FAP/seprase) as a universal marker of different cancer types. Seprase aids in the assessment of pulmonary or lung cancer (LC) or of colon cancer, e.g., of non-small cell lung carcinoma (NSCLC) or colorectal cancer (CRC), but also likely of other specific types of cancer. Such specific cancer types are, e.g., esophagus, head and neck cancer, stomach cancer, bile duct cancer, pancreas cancer, kidney cancer, cervix cancer, ovary cancer, breast cancer, bladder cancer, endometrium cancer or prostate cancer. Furthermore, it especially relates to a method for assessing cancer from a liquid sample, derived from an individual by measuring seprase in said sample. Measurement of seprase can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.
摘要翻译：本发明涉及一种协助癌症评估的方法。它公开了使用人成纤维细胞活化蛋白（FAP / seprase）作为不同癌症类型的通用标记物。 Seprase有助于评估肺或肺癌（LC）或结肠癌，例如非小细胞肺癌（NSCLC）或结肠直肠癌（CRC），但也可能是其他特定类型的癌症。这些特定的癌症类型是例如食管，头颈癌，胃癌，胆管癌，胰腺癌，肾癌，子宫颈癌，卵巢癌，乳腺癌，膀胱癌，子宫内膜癌或前列腺癌。此外，它特别涉及通过测量所述样品中的seprase从源自个体的液体样品中评估癌症的方法。 seprase的测量可以例如用于癌症的早期检测或用于进行手术的患者的监视。

27. 发明申请

US20090286328A1 USE OF PROTEIN S100A12 AS A MARKER FOR COLORECTAL CANCER 审中-公开
标题翻译：使用蛋白S100A12作为彩色癌的标记
公开(公告)号：US20090286328A1
公开(公告)日：2009-11-19
申请号：US12264324
申请日：2008-11-04
申请人： Norbert Wild , Herbert Andres , Ursula Garczarek , Andrea Geistanger , Marie-Luise Hagmann , Johan Karl , Freidemann Krause , Michael Pfeffer , Wolfgang Rollinger , Michael Tacke , Michael Thiefolf
发明人： Norbert Wild , Herbert Andres , Ursula Garczarek , Andrea Geistanger , Marie-Luise Hagmann , Johan Karl , Freidemann Krause , Michael Pfeffer , Wolfgang Rollinger , Michael Tacke , Michael Thiefolf
IPC分类号： G01N33/566
CPC分类号： G01N33/57419 , C12Q1/6886 , G01N2333/4727 , G01N2333/805 , G01N2333/8146 , G01N2333/9121
摘要： The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein S100A12 in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a stool sample, derived from an individual by measuring S100A12 in said sample. Measurement of S100A12 can, e.g., be used in the early detection or diagnosis of colorectal cancer.
摘要翻译：本发明涉及结肠直肠癌的诊断。它公开了蛋白质S100A12在结肠直肠癌诊断中的应用。它涉及一种通过测量所述样品中的S100A12从粪便样品中诊断结直肠癌的方法。 S100A12的测定可以例如用于结肠直肠癌的早期检测或诊断。

28. 发明申请

US20090075312A1 ASSESSING COLORECTAL CANCER BY MEASURING OSTEOPONTIN AND CARCINOEMBRYONIC ANTIGEN 审中-公开
标题翻译：通过测量OSTEOPONTIN和CARCINOEMBRYONIC ANTIGEN评估色素性癌
公开(公告)号：US20090075312A1
公开(公告)日：2009-03-19
申请号：US12141278
申请日：2008-06-18
申请人： Norbert Wild , Veit Peter Grunert , Johann Karl , Jarema Peter Kochan , Peter Stegmueller , Michael Tacke
发明人： Norbert Wild , Veit Peter Grunert , Johann Karl , Jarema Peter Kochan , Peter Stegmueller , Michael Tacke
IPC分类号： C12Q1/48 , G01N33/00
CPC分类号： G01N33/57419 , G01N2333/52 , G01N2333/70503
摘要： The present invention relates to a method aiding in the assessment of colorectal cancer (=CRC). It discloses the use of a marker combination comprising osteopontin and carcinoembryonic antigen in the assessment of colorectal cancer. Furthermore, it especially relates to a method for assessing colorectal cancer from a liquid sample, derived from an individual by measuring at least the markers osteopontin and carcinoembryonic antigen in said sample. The marker combination comprising osteopontin and carcinoembryonic antigen can, e.g., be used in the early detection of colorectal cancer or in the surveillance of patients who undergo therapy, e.g., surgery.
摘要翻译：本发明涉及一种协助评估结肠直肠癌（= CRC）的方法。它公开了在评估结肠直肠癌中使用包含骨桥蛋白和癌胚抗原的标记物组合。此外，它特别涉及通过至少测量所述样品中的骨桥蛋白和癌胚抗原来评估来自个体的来自液体样品的结肠直肠癌的方法。包括骨桥蛋白和癌胚抗原的标记物组合可以例如用于结肠直肠癌的早期检测或用于进行例如手术治疗的患者的监视。

29. 发明授权

US4333917A Process of producing sulfuric acid 失效
标题翻译：硫酸生产工艺
公开(公告)号：US4333917A
公开(公告)日：1982-06-08
申请号：US119289
申请日：1980-02-07
申请人： Karl H. Dorr , Helmut Diekmann , Hugo Grimm , Ulrich Sander , Michael Tacke , Waldemar Weber
发明人： Karl H. Dorr , Helmut Diekmann , Hugo Grimm , Ulrich Sander , Michael Tacke , Waldemar Weber
IPC分类号： C01B17/56 , C01B17/74 , C01B17/76 , C01B17/765 , B01D3/00 , C01B17/48 , C01B17/98
CPC分类号： C01B17/76 , C01B17/56 , C01B17/7655
摘要： A process for the production of sulfuric acid from wet sulfur dioxide containing gases is disclosed. The sulfur dioxide containing gas is initially purified and cooled, then predried with dilute sulfuric acid, finally dried with concentrated sulfuric acid, converted to sulfur trioxide catalytically and, the sulfur trioxide is absorbed in sulfuric acid. Preliminary drying removes more water than needed to maintain the water balance in the following process steps. A portion of the dilute acid from the preliminary drying is concentrated prior to recycle to the preliminary drying step and another portion of the acid from the preliminary dryer is added to the sulfur trioxide absorber to adjust the water balance in the acid circulating between the final dryer and the sulfur trioxide absorber.
摘要翻译：公开了一种从含有二氧化硫的气体生产硫酸的方法。含二氧化硫的气体最初被纯化和冷却，然后用稀硫酸预干燥，最后用浓硫酸干燥，催化转化成三氧化硫，三氧化硫被吸收在硫酸中。初步干燥除了在以下工艺步骤中维持水分平衡所需的更多的水。将预备干燥中的一部分稀酸在再循环到预干燥步骤之前进行浓缩，并将另一部分来自预干燥器的酸加入到三氧化硫吸收器中以调节在最终干燥器之间循环的酸中的水分平衡和三氧化硫吸收剂。

30. 发明授权

US09518990B2 Secernin-1 as a marker for cancer 有权
标题翻译： Secernin-1作为癌症的标志物
公开(公告)号：US09518990B2
公开(公告)日：2016-12-13
申请号：US13272399
申请日：2011-10-13
申请人： Norbert Wild , Marie-Luise Hagmann , Johann Karl , Julia Riedlinger , Markus Roessler , Michael Tacke
发明人： Norbert Wild , Marie-Luise Hagmann , Johann Karl , Julia Riedlinger , Markus Roessler , Michael Tacke
IPC分类号： G01N1/00 , G01N33/00 , G01N33/48 , G01N33/50 , G01N33/53 , G01N33/574
CPC分类号： G01N33/57484
摘要： Disclosed is a method aiding in the assessment of cancer. It involves the use of the secernin-1 protein (SCRN1) as a universal marker of different cancer types. More specifically disclosed is a method for assessing cancer from a liquid sample derived from an individual by measuring SCRN1 in the sample. Measurement of SCRN1 can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.
摘要翻译：披露了一种有助于评估癌症的方法。它涉及使用Secernin-1蛋白（SCRN1）作为不同癌症类型的通用标记物。更具体地公开了通过测量样品中的SCRN1来从源自个体的液体样品中评估癌症的方法。 SCRN1的测定可以例如用于癌症的早期检测或者进行手术的患者的监视。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式